Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

← catalyst calendar

NCT05135559

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
153estimated
Sites
91
Countries
Algeria, Bosnia and Herzegovina, Bulgaria +21

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-03-24actualWhen the study began enrolling
Primary completion2026-04-21actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2029-11-02estimatedThe whole study's end, after follow-up
First posted2021-11-26actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-13actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Haemophilia A and B With and Without Inhibitors

Intervention

  • Drug: Concizumab

Primary outcomes

what the primary-completion date above is the date OF
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
measured From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
measured From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed